Whilst the underpinning mechanisms remain to be fully elucidated in humans, the GLP-1 agonist Liraglutide has been shown to be safe and well tolerated in patients with type 2 diabetes and its use is associated with a reduction in ALT [113]. Here, GLP1R is linked to type 2 diabetes mellitus.